Introduction
Leukemogenesis is a complex process involving multiple genetic alterations that result in the abnormal regulation of proliferation, differentiation, and apoptosis of leukemic blasts, leading to their accumulation. 1 These aberrations also affect the sensitivity of leukemic cells to chemotherapeutic agents and, hence, the therapeutic outcome. Prior investigations by our group and others have established Bcl-2 as an important prognostic factor in acute myelogenous leukemia (AML) 2, 3 and have shown that inhibition of Bcl-2 expression induces apoptosis and sensitizes AML cells to chemotherapy. 4, 5 Recently, we have examined the role of the mitogen-activated protein kinase kinase (mitogen-activated protein kinase [MAPKK] or MAPK kinase [MEK] )/extracellular signalregulated kinase (ERK, hereafter referred to as MAPK) pathway, a key integration point in the signaling cascade regulated by growth factor receptors. 6 We have demonstrated that constitutive MAPK activation is frequently found in primary AML samples (74% of the cases), that it promotes AML cell growth and survival without affecting Bcl-2 expression levels, 7 and that it is independently prognostic for survival in patients with AML (S.M.K., manuscript submitted, September 2001). Albeit distinct, the Bcl-2 and MAPK pathways may crosstalk with each other, [8] [9] [10] jointly contributing to leukemogenesis. 11 Our recent evidence that constitutive MAPK activation and low, antiapoptotic Bax/Bcl-2 ratios together confer a uniformly poor prognosis on AML patients (S.M.K., manuscript submitted, September 2001) underscores the clinical relevance of such crosstalk between antiapoptotic and growth-promoting pathways and suggests that it could be exploited with therapeutic intent.
We therefore investigated whether the simultaneous inhibition of Bcl-2 (by the small-molecule inhibitor HA14-1 12 or antisense oligonucleotides [Bcl-2 AS] 5 ) and MAPK function (by the novel MEK inhibitor PD184352 13 ) resulted in increased antileukemic activity.
Study design

Cell cultures
AML cell lines (OCI-AML3, HL-60, and KG1) were cultured under standard conditions 14 and harvested in log-phase growth for every experiment. Bone marrow samples were obtained during routine diagnostic assessment after informed consent, in accordance with regulations and protocols sanctioned by the Human Subjects Committee of the University of Texas M. D. Anderson Cancer Center. Cell viability was evaluated by triplicate counting of trypan blue dye-excluding cells under a light microscope. AML blast colony assays were performed as previously described. 15 HL-60 cells stably transfected with either Bcl-2 (HL-60/Bcl-2) or empty vector control (HL-60/neo) were kindly provided by Dr K. Bhalla (Moffitt Cancer Center, University of South Florida, Tampa, FL). 16 PD184352 (2-[2-chloro-4-iodo-phenilamino]-N-cyclopropylmethoxy-3,4-difluoro-benzamide), a highly selective inhibitor of MEK activation, 13 Western blotting and apoptosis assays MAPK phosphorylation was detected by Western blot analysis as previously described. 7 To measure mitochondrial membrane potential (⌬⌿ m ), cells were loaded with CMXRos (300 nM) and MitoTracker Green (100 M, both from Molecular Probes, Eugene, OR) for 1 hour at 37°C. The ⌬⌿ m was then assessed by measuring CMXRos retention (red fluorescence) while simultaneously adjusting for mitochondrial mass (green fluorescence). 18 Caspase activation was detected by flow cytometry using a fluorescein-conjugated cell-permeable peptide (FAM-VAD-FMK) that irreversibly and selectively binds to activated caspases (caspase-1 through -9) (CaspaTag, Intergen, Purchase, NY). Annexin V binding of externalized phosphatidylserine, cell permeability, and staining of nuclear DNA were analyzed as previously published. 7
Statistical analysis
Synergism, additive effects, and antagonism were assessed using the Chou-Talalay method 19 and Calcusyn software (Biosoft, Ferguson, MO).
Briefly, the dose-effect curve for each drug alone was determined based on the experimental observations using the median-effect principle; the combination index (CI) for each experimental combination was then calculated according to the following equation:
where ( 
Results and discussion
Three AML cell lines with different degrees of MAPK activation were used in this study. In OCI-AML3 ( Figure 1A ) and HL-60 cells, which show high constitutive MAPK activity, PD184352 (10 M) rapidly (1 hour) abrogated MAPK phosphorylation by inhibiting the upstream kinase MEK. Conversely, KG1 cells showed little, if any, constitutive MAPK phosphorylation. However, PD184352 was able to abrogate phorbol myristate acetateinduced MAPK activation in these cells ( Figure 1A ). In OCI-AML3 and HL-60 cell lines, the simultaneous disruption of only.
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Bax/Bcl-2 heterodimerization by HA14-1 and interruption of MEK-to-MAPK signaling by PD184352 resulted in a striking decrease in cell viability (48 hours; Figure 1B) . Conversely, PD184352 did not significantly modify the response of KG1 cells to HA14-1 ( Figure 1B) .
We then analyzed the apoptotic response of OCI-AML3 cells to HA14-1 alone or in combination with PD184352. Consistent with the disruption of Bcl-2 function, 20 HA14-1 (12.5 M) induced rapid (2 hours) but transient mitochondrial depolarization, whereas caspase activation was detected only after 24 hours and in a smaller fraction of the cells (Figure 1C-D) . Simultaneous treatment with PD184352 (1.25 M) did not affect the early (2-6 hours) phase of HA14-1-induced mitochondrial depolarization but strikingly potentiated both loss of ⌬⌿ m and caspase activation at later times (24-48 hours; Figure 1C-D) . The apoptotic nature of the cell death triggered by simultaneous disruption of the Bcl-2 and MAPK pathways was confirmed by the exposure of phosphatidylserine on the outer leaflet of the plasma membrane and a decrease in the DNA content to sub-G 1 levels (data not shown).
The kinetics of apoptotic events observed in response to HA14-1 alone is consistent with previous results showing that mitochondrial depolarization alone, in the absence of caspase activation, cannot trigger a full apoptotic response. 21 Preliminary data from our group suggest that, in fact, AML cells that only lose ⌬⌿ m in response to HA14-1 retain substantial in vitro clonogenic ability (M.M., unpublished results, December 2001). The late potentiation observed in response to simultaneous MEK inhibition is compatible with recent evidence that the MAPK pathway protects against apoptosis at the level of cytosolic caspase activation, strongly implicating an inhibitor of apoptosis proteinlike molecule. 22 In this regard, we have recently demonstrated that MAPK inhibition specifically inhibits the expression of survivin in AML cells with constitutive MAPK activation within a compatible time frame. 7, 14 Alternatively, these 2 pathways may interact via MAPK-mediated phosphorylation of Bcl-2 itself and/or other Bcl-2 family members, such as BAD. 9, [23] [24] [25] We further analyzed the pharmacologic interactions between HA14-1 and PD184352 using a fixed-ratio experimental design and found that the simultaneous disruption of both pathways resulted in the synergistic (CI Ͻ 1.0) induction of apoptosis in cell lines showing constitutive MAPK activation (OCI-AML3 and HL-60; Figure 2A ). Moreover, the exploration of a wider range of HA14-1 and PD184352 doses using different drug ratios (2:1 to 20:1) further confirmed the synergistic nature of this interaction (Table (16); M4, diploid; previous MDS, monosomy 7) patients with more than 50% (median 61%, range 51%-79%) blasts were subjected to AML blast colony assay 15 in the presence of the indicated doses of HA14-1, alone (E) or in combination with a fixed dose of PD184352 (1.25 M, F) . Results shown represent the average Ϯ SD of the results obtained in each individual patient and are expressed as a percentage of the colony-forming unit blast in the untreated control. The mean Ϯ SD numbers of colonies in the untreated control for each individual patient were 608 Ϯ 29, 627 Ϯ 22, 584 Ϯ 27, 392 Ϯ 32, and 643 Ϯ 18, respectively (*P ϭ .015 and **P Ͻ .008 by Student t test).
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For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From 1). Conversely, the combination of HA14-1 and PD184352 at a 10:1 ratio had a slightly antagonistic effect in KG1 cells (CI Ͼ 1.2; Figure 2A and Table 1 ).
The specificity of the interaction between Bcl-2 and the MEK/MAPK module was further studied using liposome-delivered Bcl-2 AS. 5 As shown in Figure 2B , the combination of Bcl-2 AS and PD184352 at a 8:1 ratio caused substantially more apoptosis than either agent alone. Isobologram analysis confirmed that the proapoptotic interaction between Bcl-2 AS and PD184352 was indeed synergistic (CI ϭ 0.36 Ϯ 0.03; Figure 2B inset). Moreover, while Bcl-2 overexpression produced by stable gene transfer increased the resistance of HL-60-to HA14-1-induced apoptosis ( Figure 2C , left panels), this effect was overcome by simultaneous treatment with PD184352 ( Figure 2C , right panels), which shifted the 90% effective dose (ED 90 ) of HA14-1 from 32 M to 22 M (ED 90 in parental HL-60 cells, 23 M).
Although widely used and undoubtedly useful as a model to conduct mechanistic studies, culture-adapted cell lines may not accurately reflect the behavior of patient-derived cancer cells. 26 We therefore sought to confirm our cell line findings in primary AML samples. In all bone marrow samples tested in the AML blast clonogenic assay (n ϭ 5), simultaneous exposure to a fixed concentration of PD184352 (1.25 M) significantly potentiated the colony inhibitory effect of escalating doses of HA14-1 (6-12 M; Figure 2D) .
With rare exceptions, neoplastic cell growth is the result of multiple genetic alterations 27 ; therefore, any new clinically successful therapeutic strategies will most likely draw on the mechanismbased manipulation of multiple, crosstalking pathways involved in growth and survival control. From the standpoint of AML, our findings indicate that the simultaneous disruption of both the Bcl-2 and MAPK pathways synergistically induces apoptosis in cells showing constitutive MAPK activation. Because we have recently demonstrated that patients with AML with antiapoptotic Bax/Bcl-2 ratios and activated MAPK have a uniformly poor prognosis (S.M.K., manuscript submitted, September 2001), the disruption of the antiapoptotic crosstalk between the Bcl-2 and MAPK pathways could be usefully exploited for therapeutic purposes in a population of patients with AML that is currently the least responsive to conventional treatment strategies. 
